Busulfan
- Generic Name
- Busulfan
- Brand Names
- Busulfex, Myleran, Busulfan Fresenius Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C6H14O6S2
- CAS Number
- 55-98-1
- Unique Ingredient Identifier
- G1LN9045DK
- Background
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According t...
- Indication
For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia (FDA has designated busulfan as an orphan drug for this use). It is also used as a component of pretransplant conditioning regimens in patients undergoing...
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Polycythemia Vera (PV)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Gene Editing For Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT06506461
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06345495
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Northside Hospital, Inc.
- Registration Number
- NCT06337331
- Locations
- 🇺🇸
Caitlin Guzowski, Atlanta, Georgia, United States
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 10
- Registration Number
- NCT06325709
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT06252870
- Locations
- 🇫🇷
CHU Angers, Angers, France
🇫🇷CHU Brest, Brest, France
🇫🇷CHU Nantes, Nantes, France
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06207799
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
- Conditions
- Interventions
- Drug: Rabbit Anti thymocyte globulinDrug: PlerixaforBiological: Granulocyte Colony-Stimulating FactorDrug: BusulfanDrug: FludarabineDrug: ThiotepaDrug: MelphalanBiological: TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graftBiological: memory-like natural killer cellsBiological: IL-2Device: CliniMACS
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 48
- Registration Number
- NCT06158828
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06079879
- Locations
- 🇨🇳
Anhui Provincial Hospital ( Site 3513), Hefei, Anhui, China
🇨🇳Peking University Third Hospital-Hematology ( Site 3502), Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital Of Fujian Medical University ( Site 3525), Quanzhou, Fujian, China
The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
- Conditions
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT06069180
- Locations
- 🇨🇳
Deparment of Hematology, Peking University People's Hospital, Beijing, Beijing, China
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 190
- Registration Number
- NCT06001385
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Colorado Blood Cancer Institute at Presbyterian St. Luke's, Denver, Colorado, United States
🇺🇸City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.